This kit uses RT-PCR to detect recombinant c-ros oncogene 1 (ROS1) fusion gene in plasma or formalin-fixed paraffin-embedded tissue (FFPE). Test results may serve as a reference for clinical evaluation of defined ROS1 fusion gene in non-small-cell lung cancer (NSCLC) patients. Confirmed mutation: recommended medications include emtricinib, crizotinib, ceritinib, etc.
Based on high-efficiency enzymatic processing technology, the test uses specific gene sequences as PCR targets. Human genomic sequence is used as internal quality control.
